| Literature DB >> 30949426 |
Andrea Vila1, Cintia Jahan1, Cynthia Rivero1, Claudio Amadio2, Adela Ampuero3, Hugo Pagella1.
Abstract
Exophiala dermatitidis is a dematiaceous fungus with yeast-like and hyphal growth states that may cause cutaneous and visceral infections. Recently, E. dermatitidis has been linked to central line associated blood stream infection (CLABSI), probably due to its ability to produce extracellular polysaccharides and grow as biofilm. We describe an E. dermatitidis CLASBI. The strain was identified by morphological and molecular methods. E. dermatitidis CLASBI is highly uncommon, but seems to be increasing.Entities:
Keywords: Black yeast; Exophiala dermatitidis; Fungemia; Melanized fungi; Wangiella dermatitidis
Year: 2019 PMID: 30949426 PMCID: PMC6429541 DOI: 10.1016/j.mmcr.2019.03.001
Source DB: PubMed Journal: Med Mycol Case Rep ISSN: 2211-7539
Fig. 1Blood Culture fresh microscopy.
Fig. 2Culture on Sabouraud agar at 37 °C. A. Day 3: slow growing of smooth mucoid yeast-like colonies. B. After 7 days: black raised velvet colonies, suede-like in texture, olivaceous-grey with the development of aerial mycelium. Reverse is olivaceous-black.
Fig. 3Microscopic examination of culture. Hyaline budding yeast-like cells, ovoid to elliptical, with thin wall. Pigmented (dematiaceous), septate and branched hyphae, with annellidic conidiophores that produce round to ovoid conidia of different sizes, with a thin smooth wall, that accumulate in slimy balls at the apices of the annelids or down their sides forming mucosal aggregates.
Summary of published cases of E. dermatitidis CLASBI in adults excluding outbreaks.
| Author Country Year Reference | Sex Age | Comorbidities at time of diagnosis | Site of isolation | Susceptibility MIC (μg/mL) | Treatment | Outcome |
|---|---|---|---|---|---|---|
| Simpson UK 1995 [ | F | CVC | 2 CVC-BC Morphotype | Not done | CVC removal Fluconazole | Survived |
| Larocco USA 2002 [ | F | Metastatic breast cancer Chemotherapy TI-CVAD | 1 P-BC Morphotype | Not done | CVC removal | Survived |
| Tseng Taiwan 2005 [ | F 52 | Metastatic lung cancer | 2 CVC-BC | Fluconazole 48 | CVC removal | Died |
| Chalkias USA 2014 [ | M 57 | Relapsed lymphoma HSCT | 5 pairs of P-BC* Morphological and biochemical properties | Fluconazole 8 | CVC removal | Died |
| Kakuya | F | Metastatic lingual and esophageal cancer | TI-CVAD culture Morphotype | Mica >16 | CVC removal | Died |
| Watanabe | M, 45 | Myelofibrosis | P-BC* | AB: 0.5 | CVC removal | Died |
| Morphotype | MCFG: > 16 | |||||
| MALDI-TOF | FLCZ: 16 | |||||
| Our case | M, 75 | Cirrhosis | 6 BCs | AB 0.125 | CVC removal | Dead |
F: female; M: male; CVC: central venous catheter; BC: blood-culture; P: peripheral; TI-CVAD: totally implanted central venous access device; AB: amphotericin B; 5-FC: 5-flucytosine; HSCT: hematopoietic stem cell transplant; GVHD: graft-versus-host disease; PICC: peripherally inserted central line; L-AB: liposomal amphotericin; TRF: terbinafine; UCBT: umbilical cord blood transplantation; COPD: chronic obstructive pulmonary disease; ITS: internal transcribed spacer.
*Note: fungemia while on mica prophylaxis.